Tokyo, Jan 19, 2012 - (JCN Newswire) - Eisai Co. Ltd and its diagnostics subsidiary EIDIA Co. Ltd announced today that EIDIA will launch LIFE CHECK, a self-monitoring blood glucose meter manufactured by Gunze Limited, on January 27, 2012.
LIFE CHECK is a personal self-monitoring blood glucose meter with which diabetes patients can monitor their own blood glucose level by simply inserting a dedicated sensor known as the LIFE CHECK SENSOR into the meter. The meter was developed as a next-generation model of the blood glucose monitor G-CHECK currently manufactured by Gunze and marketed by EIDIA. While Gunze received approval to manufacture and market LIFE CHECK in August 2011, the system will be distributed and marketed by EIDIA and co-promoted by Eisai.
The LIFE CHECK meter employs a color liquid crystal screen that displays step-by-step operational instructions and easy-to-read graphs of measured data. After measurement, the dedicated sensor can be easily and safely removed from the meter with the push of a button without the patient having to touch the part to which their blood has been applied. The meter has been specially designed for ease-of-use by elderly diabetes patients. The sensor is easily inserted into the meter and has been designed to ensure that drops of blood from pierced fingertips can be easily applied. It can even be used simply by diabetes patients who experience numbness and trembling in their hands and fingers.
Diabetes is a disease that causes an inability to produce insulin or abnormal insulin sensitivity, with patients being unable to control the amount of glucose in their blood (blood glucose level). In Japan, the number of patients with the disease has been increasing every year in accordance with changes in lifestyles and social environments. Eisai, EIDIA and Gunze seek to make further contributions to increase the benefits provided to patients living with diabetes.
About Eisai
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Contact:
Public Relations Department
Eisai Co. Ltd
T: +81-(0)3-3817-5120
Jan 19, 2012
Source: Eisai
Eisai (TSE: 4523) (U.S: ESALY)
From the Japan Corporate News Network
http://www.japancorp.net
Topic: New Product
View more news from these Sectors: Biotech, Medical
|
